CIRI Opens Coronavirus Clinical Trials
The CHI Institute for Research and Innovation (CIRI) has opened two clinical trials for treatment of patients with COVID-19 at CHI Franciscan St. Joseph Medical Center in Tacoma, WA:
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)
The primary objective of this study is to evaluate the efficacy of two remdesivir (RDV) regimens with respect to the normalization of temperature and oxygen saturation through Day 14 in participants with severe coronavirus disease (COVID-19).
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment
The primary objective of this study is to evaluate the efficacy of two remdesivir (RDV) regimens compared to standard of care (SOC), with respect to the time to discharge in participants with moderate coronavirus disease (COVID-19).
For more information, please contact Diana Morales or Conchita Purchase.
U.S. COVID-19 cases surpass 18 million
DEC 29, 2020Dr. Thomas McGinn, executive vice president of Physician Enterprise, discussed the current state of the pandemic, the vaccine rollout, and growth in virtual care.
Don’t Share Your Air
DEC 22, 2020As the COVID-19 pandemic reaches new heights in communities across the country, CHI provides a simple prescription: Don’t Share Your Air.
CHI Health doctors, nurses celebrate COVID-19 vaccine
DEC 15, 2020Health care workers at CHI Health receive their first doses of the COVID-19 vaccine.